TP53 and breast carcinoma: Callagy et al. (2006) have also found that BCL-2 was the only marker from a panel of 13 proteins (HER2, c-Myc, cyclin E, CK5/6, CK17, CK8/18, ER, Ki-67, MCM-2, p27, P53 and PgR) that improved prognostication in the group of 930 breast cancer patients, some of whom were treated with adjuvant CT.